Dange Vijaykumar

Summary

Publications

  1. ncbi Discovery of novel hydroxy pyrazole based factor IXa inhibitor
    Dange Vijaykumar
    Celera, 180 Kimball Way, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:2796-9. 2006
  2. ncbi Efforts toward oral bioavailability in factor VIIa inhibitors
    Dange Vijaykumar
    Celera, 180 Kimball Way, South San Francisco, CA 94979, USA
    Bioorg Med Chem Lett 16:3829-32. 2006
  3. ncbi Novel 5-azaindole factor VIIa inhibitors
    Jennifer R Riggs
    Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:3197-200. 2006
  4. ncbi Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability
    Jennifer R Riggs
    Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:2224-8. 2006
  5. ncbi Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand: [18F] propyl pyrazole triol
    Dange Vijaykumar
    Department of Chemistry, University of Illinois, 600 S. Mathews Avenue, Urbana, Illinois 61801, USA
    Nucl Med Biol 30:397-404. 2003

Detail Information

Publications5

  1. ncbi Discovery of novel hydroxy pyrazole based factor IXa inhibitor
    Dange Vijaykumar
    Celera, 180 Kimball Way, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:2796-9. 2006
    ..Synthesis and biological data of a novel selective and efficacious factor IXa inhibitor are described along with its crystal structure in factor VIIa...
  2. ncbi Efforts toward oral bioavailability in factor VIIa inhibitors
    Dange Vijaykumar
    Celera, 180 Kimball Way, South San Francisco, CA 94979, USA
    Bioorg Med Chem Lett 16:3829-32. 2006
    ..Efforts toward developing orally bioavailable factor VIIa inhibitors starting from parenteral lead compound 1 are described. SAR resulted in improved physicochemical properties, leading to enhanced oral absorption in rat...
  3. ncbi Novel 5-azaindole factor VIIa inhibitors
    Jennifer R Riggs
    Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:3197-200. 2006
    ..The discovery and development of 5-azaindole factor VIIa inhibitors will be described...
  4. ncbi Factor VIIa inhibitors: a prodrug strategy to improve oral bioavailability
    Jennifer R Riggs
    Celera Genomics, 180 Kimball Way, South San Francisco, CA 94080, USA
    Bioorg Med Chem Lett 16:2224-8. 2006
    ..Herein, we describe our efforts to improve the oral bioavailability of the parent amidine via a prodrug strategy where the amidine basicity and polarity were reduced with either an alkoxy-amidine or a carbamate prodrug...
  5. ncbi Synthesis and biological evaluation of a fluorine-18 labeled estrogen receptor-alpha selective ligand: [18F] propyl pyrazole triol
    Dange Vijaykumar
    Department of Chemistry, University of Illinois, 600 S. Mathews Avenue, Urbana, Illinois 61801, USA
    Nucl Med Biol 30:397-404. 2003
    ....